Thromboxane b2

Thromboxane b2 is a lipid of Fatty Acyls (FA) class. Thromboxane b2 is associated with abnormalities such as endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia and Thrombocytosis. The involved functions are known as Platelet Activation, Excretory function, Anabolism, Inflammation and mRNA Expression. Thromboxane b2 often locates in Endothelium, Hepatic and Microsomes, Liver. The associated genes with Thromboxane b2 are PTGS2 gene, prothrombin fragment 2 and CCL14 wt Allele.

Cross Reference

Introduction

To understand associated biological information of Thromboxane b2, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Thromboxane b2?

Thromboxane b2 is suspected in endothelial dysfunction, Diabetes Mellitus, Non-Insulin-Dependent, Diabetes Mellitus, Ischemia, Thrombocytosis, Acute Coronary Syndrome and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Thromboxane b2

MeSH term MeSH ID Detail
Abortion, Habitual D000026 5 associated lipids
Acidosis D000138 13 associated lipids
Adenocarcinoma D000230 166 associated lipids
Agranulocytosis D000380 7 associated lipids
Airway Obstruction D000402 13 associated lipids
Albuminuria D000419 18 associated lipids
Alcoholic Intoxication D000435 15 associated lipids
Anaphylaxis D000707 35 associated lipids
Anemia D000740 21 associated lipids
Anemia, Sickle Cell D000755 34 associated lipids
Angina Pectoris D000787 27 associated lipids
Angina Pectoris, Variant D000788 3 associated lipids
Angina, Unstable D000789 14 associated lipids
Hypoxia D000860 23 associated lipids
Aortic Aneurysm D001014 8 associated lipids
Aortic Arch Syndromes D001015 2 associated lipids
Aortic Rupture D001019 3 associated lipids
Arrhythmias, Cardiac D001145 42 associated lipids
Arterial Occlusive Diseases D001157 12 associated lipids
Arteriosclerosis D001161 86 associated lipids
Per page 10 20 50 100 | Total 293

PubChem Associated disorders and diseases

What pathways are associated with Thromboxane b2

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Thromboxane b2?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Thromboxane b2?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

What genes are associated with Thromboxane b2?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Thromboxane b2?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with Thromboxane b2

Download all related citations
Per page 10 20 50 100 | Total 6367
Authors Title Published Journal PubMed Link
Ersöz G et al. Effect of submaximal and incremental upper extremity exercise on platelet function and the role of blood shear stress. 2002 Thromb. Res. pmid:12676189
Ushiyama S et al. RS-5186, a novel thromboxane synthetase inhibitor with a potent and extended duration of action. 1988 Thromb. Res. pmid:3175990
Svensson J and Samuelsson K Inhibition of platelet function by low dose acetylsalicylic acid in patients with cerebrovascular disease. 1983 Thromb. Res. pmid:20218005
Rogasi PG et al. Radioimmunoassay of thromboxane B2 in plasma: methodological modifications. 1988 Thromb. Res. pmid:3175991
Weide I and Simmet T Leukotriene formation by peripheral monocytes in contact-activated human blood. 1993 Thromb. Res. pmid:8211886
Takasaki W et al. Superiority of plasma 11-dehydro-TXB2 to TXB2 as an index of in vivo TX formation in rabbits after dosing of CS-518, a TX synthase inhibitor. 1993 Thromb. Res. pmid:8367836
Saldeen P et al. Increased synthesis of thromboxane B2 and 6-keto-PGF1 alpha in hand veins from patients with deep venous thrombosis. 1983 Thromb. Res. pmid:6658723
Bradlow BA and Chetty N Dosage frequency for suppression of platelet function by low dose aspirin therapy. 1982 Thromb. Res. pmid:7123514
Buchanan MR et al. Aspirin inhibits platelet function independent of the acetylation of cyclo-oxygenase. 1982 Thromb. Res. pmid:7071811
Butler KD et al. Prolongation of platelet survival in hypercholesterolaemic rabbits by CGS 12970 (3-methyl-2-(3-pyridyl)-1 indoleoctanoic acid) and dazoxiben. 1987 Thromb. Res. pmid:3109067
Boyd JA and Eling TE Prostaglandin release and the interaction of platelets with the pulmonary vasculature of rat and guinea pig. 1980 Jul 1-15 Thromb. Res. pmid:7003800
Martin JF et al. Effect of acetylsalicylic acid on platelet aggregation and thromboxane B2 production in flowing aortic blood in the rat studied with a filter loop technique. 1982 Thromb. Res. pmid:6814004
Mikashima H and Muramoto Y Protective effect of Y-20811, a long-lasting thromboxane synthetase inhibitor, on endotoxin shock in rabbits. 1990 Thromb. Res. pmid:2326771
Agren JJ et al. Dose responses in platelet fatty acid composition, aggregation and prostanoid metabolism during moderate freshwater fish diet. 1990 Thromb. Res. pmid:2326774
Pedersen AK et al. Inhibition of thromboxane biosynthesis in serum: limitations of the measurement of immunoreactive 6-keto-PGF1 alpha. 1984 Thromb. Res. pmid:6546456
Grauso F et al. Effects of iloprost (ZK 36374), a prostacyclin derivative, on platelet function after ischaemic exercise in patients with stable angina pectoris. 1987 Thromb. Res. pmid:2447664
Saldeen P et al. Thromboxane production in umbilical vein grafts. 1984 Thromb. Res. pmid:6546814
Udvardy M et al. Plasma thromboxane and prostacyclin metabolite ratio in atherosclerosis and diabetes mellitus. 1987 Thromb. Res. pmid:3116717
García Frade LJ et al. Diabetes mellitus as a hypercoagulable state: its relationship with fibrin fragments and vascular damage. 1987 Thromb. Res. pmid:3118498
Davì G et al. Thromboxane B2 formation and platelet sensitivity to prostacyclin in insulin-dependent and insulin-independent diabetics. 1982 Thromb. Res. pmid:6761893
Tsuboi T et al. Effect of gliclazide on prostaglandin and thromboxane synthesis in guinea-pig platelets. 1981 Jan 1-15 Thromb. Res. pmid:7233394
Ditter H et al. Effects of prostacyclin during cardiopulmonary bypass in men on plasma levels of beta-thromboglobulin, platelet factor 4, thromboxane B2, 6-keto-prostaglandin F1 alpha and heparin. 1983 Thromb. Res. pmid:6197766
Rostagno C et al. In vitro effects of two novel calcium antagonists (nitrendipine and nisoldipine) on intraplatelet calcium redistribution, platelet aggregation and thromboxane A2 formation. Comparison with diltiazem, nifedipine and verapamil. 1991 Thromb. Res. pmid:1754998
Castaldi PA et al. Evidence for a platelet membrane defect in the myeloproliferative syndromes. 1982 Thromb. Res. pmid:6960545
Gachályi B et al. In vitro effect of cimetidine on ADP induced platelet aggregation and thromboxane A2 synthesis in man. 1984 Thromb. Res. pmid:6474407
Fitzpatrick F et al. Development of a gas chromatographic-mass spectrometric method using a stable isotope internal standard for quantitation of thromboxane B2. 1984 Thromb. Res. pmid:6474413
Dalli E et al. Effects of hawthorn (Crataegus laevigata) on platelet aggregation in healthy volunteers. 2011 Thromb. Res. pmid:21737127
Toivanen J et al. Differential inhibition of platelet thromboxane and lung prostacyclin production by sulphinpyrazone, acetylsalicylic acid and indomethacin by human tissues in vitro. 1985 Thromb. Res. pmid:3920778
Ishii H et al. The effect of plasma on platelet function in hypercholesterolemic rabbits and the changes in fatty acid composition of the plasma. 1984 Thromb. Res. pmid:6234679
Catella F and FitzGerald GA Paired analysis of urinary thromboxane B2 metabolites in humans. 1987 Thromb. Res. pmid:3686481
Arruzazabala ML et al. Effects of Policosanol on platelet aggregation in rats. 1993 Thromb. Res. pmid:8475481
Reis F et al. The peripheral serotonergic system and platelet aggregation in cyclosporin A-induced hypertensive rats. 1999 Thromb. Res. pmid:10605951
Weide I et al. Effects of cyclooxygenase inhibitors on ex vivo cysteinyl-leukotriene production by whole human blood allowed to clot spontaneously. Comparison to stimulated blood. 1992 Thromb. Res. pmid:1440511
Patrono C et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. 1980 Feb 1-15 Thromb. Res. pmid:7368167
Lin CH et al. HA-29: an inhibitor of thromboxane A2 formation with antagonism of thromboxane A2/prostaglandin endoperoxide receptor in rabbit platelets. 1992 Thromb. Res. pmid:1412184
Tindall H et al. Thrombin generation precedes platelet activation in native blood taken from the hand during multiple blood sampling following cold challenge. 1987 Thromb. Res. pmid:3617016
Mannucci L et al. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk. 1987 Thromb. Res. pmid:3445229
Chakroun T et al. Screening for aspirin resistance in stable coronary artery patients by three different tests. 2007 Thromb. Res. pmid:17553552
Simmet T and Luck W Clotting of whole human blood induces cysteinyl-leukotriene formation. 1989 Thromb. Res. pmid:2549655
Winther K et al. Platelet function and fibrinolytic activity in cervical spinal cord injured patients. 1992 Thromb. Res. pmid:1321515
Chetty N and Bradlow BA The effects of a vegetarian diet on platelet function and fatty acids. 1983 Thromb. Res. pmid:6612688
Best LC et al. Mode of action of dipyridamole on human platelets. 1979 Thromb. Res. pmid:229583
Jørgensen KA et al. The survival of pig to rabbit renal xenografts during inhibition of thromboxane synthesis. 1983 Thromb. Res. pmid:6364449
Tanoue K et al. A new variant of thrombasthenia with abnormally glycosylated GP IIb/IIIa. 1987 Thromb. Res. pmid:3629560
Naran NH and Chetty N The in vitro effect of ridogrel on platelet function in normocholesterolaemic and familial hypercholesterolaemic type IIa subjects. 1997 Thromb. Res. pmid:9556227
Altman R and Scazziota A Synergistic actions of paf-acether and sodium arachidonate in human platelet aggregation. 2. Unexpected results after aspirin intake. 1986 Thromb. Res. pmid:3088757
Franconi F et al. Effect of gamma-hydroxybutyric acid on human platelet aggregation in vitro. 2001 Thromb. Res. pmid:11369419
Petroni A et al. Inhibition of platelet aggregation and eicosanoid production by phenolic components of olive oil. 1995 Thromb. Res. pmid:7482432
Kudolo GB et al. Effect of the ingestion of Ginkgo biloba extract on platelet aggregation and urinary prostanoid excretion in healthy and Type 2 diabetic subjects. 2002 Thromb. Res. pmid:12590952
Todd MH et al. The involvement of prostaglandins and thromboxanes in the response to pulmonary embolism in anaesthetized rabbits and isolated perfused lungs. 1983 Thromb. Res. pmid:6687961
Barnhart MI et al. DDAVP: does the drug have a direct effect on the vessel wall? 1983 Thromb. Res. pmid:6415852
Davì G et al. Inhibition of platelet function by ticlopidine in arteriosclerosis obliterans of the lower limbs. 1985 Thromb. Res. pmid:2933846
Saldeen P and Saldeen T 6-keto-prostaglandin F1 alpha/thromboxane B2 ratio in vascular and lung tissue. 1983 Thromb. Res. pmid:6688484
Teng CM et al. Inhibition of thrombin- and collagen-induced phosphoinositides breakdown in rabbit platelets by a PAF antagonist--denudatin B, an isomer of kadsurenone. 1990 Thromb. Res. pmid:2169076
Platelet function during long-term treatment with ketanserin of claudicating patients with peripheral atherosclerosis. A multi-center, double-blind, placebo-controlled trial. The PACK Trial Group. 1989 Thromb. Res. pmid:2528841
Pattison A et al. The in vitro effect of amrinone on thromboxane B2 synthesis in human whole blood. 1986 Thromb. Res. pmid:3755259
Yue TL et al. Pharmacological profile of G619, a new platelet aggregation inhibitor. 1992 Thromb. Res. pmid:1412200
Russell NH et al. Platelet adenine nucleotides and arachidonic acid metabolism in the myeloproliferative disorders. 1981 Thromb. Res. pmid:6794179
Lagarde M et al. Increase of platelet thromboxane A2 formation and of its plasmatic half-life in diabetes mellitus. 1980 Thromb. Res. pmid:7466751
Dupin JP et al. In vitro antiaggregant activity of paracetamol and derivatives. 1988 Thromb. Res. pmid:3134743
Togna GI et al. Cisplatin triggers platelet activation. 2000 Thromb. Res. pmid:10973681
Saloheimo P et al. Thromboxane and prostacyclin biosynthesis in patients with acute spontaneous intracerebral hemorrhage. 2005 Thromb. Res. pmid:15733969
Kelton JG et al. A study of the bioavailability and platelet inhibitory effects of a new enteric-coated acetylsalicylic acid preparation. 1984 Thromb. Res. pmid:6740573
Grimm LJ et al. Inhibition of platelet thromboxane synthesis by 7-(1-imidazolyl) heptanoic acid: dissociation from inhibition of aggregation. 1981 Thromb. Res. pmid:6801806
Uyama O et al. Plasma concentrations of 6-keto-prostaglandin F1 alpha in patients with hypertension, cerebrovascular disease or Takayasu's arteritis. 1982 Jan 1-15 Thromb. Res. pmid:6121391
Voss R et al. In vitro and ex vivo effects of aspirin in patients on a low-dose aspirin therapy. 1993 Thromb. Res. pmid:8122187
Hashizume T et al. Vinblastine inhibits platelet aggregation by a microtubule-independent mechanism, probably by its perturbing action on the plasma membrane. 1988 Thromb. Res. pmid:3135636
Chou TC et al. The inhibitory effect of 2-thienyl 2'-hydroxyphenyl ketone (C85) on platelet thromboxane formation. 1996 Thromb. Res. pmid:8897698
Teng CM et al. Antiplatelet actions of some coumarin compounds isolated from plant sources. 1992 Thromb. Res. pmid:1523611
Takasaki W et al. Enzyme immunoassay of human plasma 11-dehydrothromboxane B2. 1991 Thromb. Res. pmid:1957275
Korth R et al. Unsaturated platelet-activating factor: influence on aggregation, serotonin release and thromboxane synthesis of human thrombocytes. 1986 Thromb. Res. pmid:3961742
Schmid P et al. Passive smoking and platelet thromboxane. 1996 Thromb. Res. pmid:8907294
Preston FE et al. Low-dose aspirin inhibits platelet and venous cyclo-oxygenase in man. 1982 Thromb. Res. pmid:6815823
Pinto S et al. No signs of increased thrombin generation in menopause. 1990 Thromb. Res. pmid:2201101
Riess H et al. Thromboxane receptor blockade versus cyclooxigenase inhibition: antiplatelet effects in patients. 1986 Thromb. Res. pmid:3012819
Randall MJ et al. UK-37, 248, a novel, selective thromboxane synthetase inhibitor with platelet anti-aggregatory and anti-thrombotic activity. 1981 Jul 1-15 Thromb. Res. pmid:6795753
Altman R et al. Synergistic actions of PAF-acether and sodium arachidonate in human platelet aggregation. 1. Studies in normal human platelet rich plasma. 1986 Thromb. Res. pmid:3014677
Teng CM et al. Platelet aggregation induced by equinatoxin. 1988 Thromb. Res. pmid:2906181
Armstrong RA et al. No effect of dietary trans isomers of alpha-linolenic acid on platelet aggregation and haemostatic factors in european healthy men. The TRANSLinE study. 2000 Thromb. Res. pmid:11108899
De La Cruz JP et al. Effect of DT-TX 30, a combined thromboxane synthase inhibitor and thromboxane receptor antagonist, on retinal vascularity in experimental diabetes mellitus. 2000 Thromb. Res. pmid:10680643
Weber AA et al. 40 mg of aspirin are not sufficient to inhibit platelet function under conditions of limited compliance. 2000 Thromb. Res. pmid:10709913
Wu TM et al. Inhibitory effect of hexapeptide (RGRHGD) on platelet aggregation. 2000 Thromb. Res. pmid:10674405
Leoncini G et al. In retinal vein occlusion platelet response to thrombin is increased. 2009 Thromb. Res. pmid:19660790
Shatoor AS et al. Effect of Hawthorn (Crataegus aronia syn. Azarolus (L)) on platelet function in albino Wistar rats. 2012 Thromb. Res. pmid:22261477
Perneby C et al. Optimization of an enzyme immunoassay for 11-dehydro-thromboxane B(2) in urine: comparison with GC-MS. 1999 Thromb. Res. pmid:10632465
Prosdocimi M et al. Inhibition by AD6 (8-monochloro-3-beta-diethylaminoethyl-4-methyl-7-ethoxycarbonyl methoxy coumarin) of platelet aggregation in dog stenosed coronary artery. 1985 Thromb. Res. pmid:3840290
Driss F et al. Inhibition of platelet aggregation and thromboxane synthesis after intake of small amount of icosapentaenoic acid. 1984 Thromb. Res. pmid:6098051
Carter AJ and Jones EW The effect of the degree of diabetic control on thromboxane synthesis in clotted whole blood. 1986 Thromb. Res. pmid:3515613
Mogensen F et al. Effect of specific thromboxane-synthetase inhibition on thromboxane and prostaglandin synthesis in stable angina induced by exercise test. 1985 Thromb. Res. pmid:4038824
Tzeng SH et al. Inhibition of platelet aggregation by some flavonoids. 1991 Thromb. Res. pmid:1776142
Neiman J et al. Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. 1989 Thromb. Res. pmid:2617478
Neiman J et al. Platelet uptake of serotonin (5-HT) during ethanol withdrawal in male alcoholics. 1987 Thromb. Res. pmid:2820078
Zahavi M et al. Enhanced platelet release reaction and increased thromboxane generation in esophageal achalasia and selective in vitro inhibition of arachidonic acid induced platelet aggregation by vasoactive intestinal peptide. 1990 Thromb. Res. pmid:2146767
De la Cruz JP et al. Effect of erythrocytes and prostacyclin production in the effect of fructose and sorbitol on platelet activation in human whole blood in vitro. 1997 Thromb. Res. pmid:9219331
Weigel G et al. Regulation of eicosanoid release in human umbilical endothelial cells. 1991 Thromb. Res. pmid:1656543
Ko FN et al. Antiplatelet effects of protopine isolated from Corydalis tubers. 1989 Thromb. Res. pmid:2559491
Ito T et al. Role of activated platelets in endotoxin-induced DIC in rats. 1990 Thromb. Res. pmid:2080492
Alessandrini P et al. Physiologic variables affecting thromboxane B2 production in human whole blood. 1985 Thromb. Res. pmid:3983893
Lukaszyk A et al. Blood platelet function in canine acute pancreatitis with reference to treatment with Nafamostat mesilate (FUT-175). 1992 Thromb. Res. pmid:1579898
Grignani G et al. Activation of platelet prostaglandin biosynthesis pathway during neoplastic cell-induced platelet aggregation. 1984 Thromb. Res. pmid:6729776